Medicus Pharma Signs SPAC LOI to Spin Out SkinJect in $135 Million Business Combination

A SPAC-driven spinout of Medicus Pharma's SkinJect subsidiary signals a financing model that contract manufacturing partners and regulatory strategy teams supporting small-cap rare-disease programs should track closely. Under a non-binding letter of intent announced 4 November 2026, SkinJect, Inc. would merge with an undisclosed SPAC at a pre-money enterprise valuation of $135 million, with concurrent equity financing earmarked specifically for the SKNJCT-005 NDA-enabling registrational study in Gorlin syndrome patients.

The structure preserves Medicus majority economic and voting ownership post-combination while establishing SkinJect as a separately listed public entity. Final ownership percentages remain subject to negotiation, with dilutive variables including retained SPAC cash, sponsor shares, and warrants all unresolved at the LOI stage. Medicus anticipates closing in the first half of 2027, contingent on satisfactory due diligence, definitive agreement execution, SEC registration, minimum-cash conditions, and stock exchange listing approval.

For regulatory affairs leads, the clinical context is material. SkinJect is an investigational dissolvable microneedle-array patch delivering doxorubicin directly into basal cell carcinoma lesions. The FDA has issued a Study May Proceed letter authorizing initiation of SKNJCT-005, a Phase 2b study designed to generate the data package required for a potential NDA submission. Gorlin syndrome, a rare genetic condition driving multiple recurrent basal cell carcinomas, qualifies the program for rare-disease regulatory pathways that can affect review timelines and CMC documentation expectations.

For CMOs and CDMOs already supporting or evaluating the SkinJect program, the spinout structure introduces a distinct counterparty once definitive agreements are signed. Supply agreements, quality technical agreements, and any process validation commitments tied to the NDA-enabling study will need to reflect the new legal entity. The concurrent financing is intended to fund that study, but the LOI carries no assurance that financing will close or that the transaction will complete on the anticipated schedule.

The transaction remains non-binding except for limited procedural provisions, and Medicus has stated explicitly that no assurance exists that definitive agreements will be executed or that the combination will close.

The measurable checkpoint for both regulatory and manufacturing stakeholders is the SKNJCT-005 study initiation timeline, which will determine whether the NDA submission window aligns with the projected H1 2027 close.

Source: Medicus Pharma Ltd. via GlobeNewswire, 4 November 2026.